Walking Fish has created a broad B cell platform for oncology, regenerative medicine, autoimmune disease, and recombinant antibody production. As a leader in B cell engineering, Walking Fish has made critical advances in engineering technologies and has a deep understanding about B cell biology. The WFT team includes experienced researchers excited about our new approach to the treatment of severe diseases.
Location: United States, California, South San Francisco
Employees: 11-50
Total raised: $23M
Founded date: 2019
Investors 2
| Date | Name | Website |
| - | Illumina V... | illuminaVe... |
| - | First Spar... | firstspark... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 16.02.2022 | Series A | $23M | - |
Mentions in press and media 3
| Date | Title | Description |
| 16.02.2022 | Walking Fish Therapeutics Raises $73M in Series A Financing | Walking Fish Therapeutics, a South San Francisco, Calif.-based leader in B cell therapeutics, closed a $73m Series A financing. The round was co-led by Northpond Ventures and First Spark Ventures, with participation from Terra Magnum Capita... |
| 13.09.2021 | The Apple vs. Epic fight isn’t over | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Paid Content How a global community of chief executives is building better leaders From YPO On Fr... |
| 13.09.2021 | Walking Fish Therapeutics Raises $50M in Series A Financing | Walking Fish Therapeutics, a South San Francisco, CA-based B cell engineering company, closed a $50M Series A financing. The round was led led by Emerson Collective, Illumina Ventures and Quan Capital. Co-founded by CEO Dr. Lewis “Rusty” Wi... |